Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.69), $0.08 better than the analyst estimate of ($0.77).

“The COVID-19 pandemic has given rise to unprecedented circumstances for Editas and the broader life sciences community,” said Cynthia Collins, Chief Executive Officer of Editas Medicine. “Our top priority is safety and we have implemented measures to ensure that safety comes first while mitigating the disruption to our business operations as much as possible. I want to thank our employees, patients, and partners for their resilience during this difficult time.”

Ms. Collins continued, “Despite these obstacles, 2020 has been a momentous year for Editas. We are incredibly proud to have advanced an entirely new class of medicines to the clinic with the first ever administration of EDIT-101, our in vivo CRISPR gene editing medicine for LCA10. In addition, we expect continued execution throughout 2020 which will include the expansion of our clinical programs through an expected IND filing for EDIT-301, our first engineered cell medicine and potentially best-in-class treatment for sickle cell disease and beta-thalassemia.”

Recent Achievements and Outlook

Business Outlook

COVID-19 ImpactPotential business interruptions due to the COVID-19 outbreakEditas Medicine (Company) continues to evaluate the impact of the global COVID-19 pandemic on the continuity of the Company’s research, clinical trial activity, and business outlook. The Company has taken numerous steps to protect its employees, patients, and partners, while working to ensure the productivity of its business operations. As of March 12, the Company transitioned to remote working for office-based personnel. In addition, essential laboratory, manufacturing, and related support activities have been subject to precautionary measures to ensure the safety of our workforce.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.